Compare RRGB & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRGB | XGN |
|---|---|---|
| Founded | 1969 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.4M | 71.2M |
| IPO Year | 2002 | 2014 |
| Metric | RRGB | XGN |
|---|---|---|
| Price | $4.50 | $4.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $9.00 | $8.86 |
| AVG Volume (30 Days) | 462.8K | ★ 481.3K |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,315,014,000.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $2.59 |
| 52 Week High | $7.52 | $12.23 |
| Indicator | RRGB | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.24 | 72.26 |
| Support Level | $3.84 | $2.68 |
| Resistance Level | $5.29 | $6.75 |
| Average True Range (ATR) | 0.35 | 0.39 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 70.00 | 96.15 |
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.